Company Filing History:
Years Active: 2020
Title: Mi Huang - Innovator in Cancer Therapy
Introduction
Mi Huang is a prominent inventor based in Wuhan, China. She has made significant contributions to the field of cancer therapy through her innovative research and development. Her work focuses on enhancing the efficacy of cancer treatments using bispecific antibodies.
Latest Patents
Mi Huang holds 1 patent for her invention titled "Bispecific antibody-mediated cancer therapy with cytokine-induced killer cell." This patent provides compositions that comprise a MSBODY and a cytotoxic immune cell, such as Cytokine-induced killer cells, to form Armed Activated CIK cells (ACCs). The MSBODY includes a first antigen binding moiety that specifically targets a tumor antigen and a second antigen binding moiety that binds to the immune cell. The patent also outlines methods for preparing these compositions and treating patients with CIK cells armed with bispecific antibodies.
Career Highlights
Mi Huang is associated with Wuhan Yzy Biopharma Co., Ltd., where she continues to advance her research in cancer therapies. Her innovative approach has the potential to significantly improve treatment outcomes for cancer patients.
Collaborations
Mi Huang collaborates with notable colleagues, including Pengfei Zhou and Tao Wang, who contribute to her research efforts in the field of immunotherapy.
Conclusion
Mi Huang's work in bispecific antibody-mediated cancer therapy represents a significant advancement in the fight against cancer. Her innovative approaches and collaborations are paving the way for more effective treatments in the future.